124 related articles for article (PubMed ID: 7493311)
21. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
22. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
[TBL] [Abstract][Full Text] [Related]
24. Interferon alpha for eradication of HCV and remission of chronic hepatitis in children.
Majda-Stanisławska E; Szaflik I; Omulecka A
Med Sci Monit; 2000; 6(6):1142-7. PubMed ID: 11208470
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.
Sherman KE; Sjogren M; Creager RL; Damiano MA; Freeman S; Lewey S; Davis D; Root S; Weber FL; Ishak KG; Goodman ZD
Hepatology; 1998 Apr; 27(4):1128-35. PubMed ID: 9537454
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection.
Yao GB; Fu XX; Tian GS; Xu DZ; Hao LJ; Huangfu YS; Su CX
J Gastroenterol Hepatol; 2000 Oct; 15(10):1165-70. PubMed ID: 11106097
[TBL] [Abstract][Full Text] [Related]
27. alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia.
Di Marco V; Lo Iacono O; Capra M; Grutta S; Ciaccio C; Gerardi C; Maggio A; Renda D; Almasio P; Pisa R
Haematologica; 1992; 77(6):502-6. PubMed ID: 1289187
[TBL] [Abstract][Full Text] [Related]
28. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
29. [Studies on the treatment of chronic hepatitis C with interferon. Assessment of treatment regimens and response to treatment].
Ueda Y; Aramaki T; Kumada H
Nihon Ika Daigaku Zasshi; 1993 Jun; 60(3):173-85. PubMed ID: 8331152
[TBL] [Abstract][Full Text] [Related]
30. Lymphoblastoid interferon in chronic hepatitis C patients who were "non responders" to recombinant interferon alpha (rIFN alpha).
Budillon G; Cimino L; D'Ascoli B; Napolitano PV
Arch Virol Suppl; 1993; 8():249-55. PubMed ID: 8260870
[TBL] [Abstract][Full Text] [Related]
31. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
Neri S; Pistone G; Saraceno B; Pennisi G; Luca S; Malaguarnera M
Neuropsychobiology; 2003; 47(2):94-7. PubMed ID: 12707492
[TBL] [Abstract][Full Text] [Related]
32. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients.
Marriott E; Navas S; del Romero J; García S; Castillo I; Quiroga JA; Carreño V
J Med Virol; 1993 Jun; 40(2):107-11. PubMed ID: 8395552
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
36. Recombinant interferon-alpha-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study.
Imai Y; Kawata S; Tamura S; Ito N; Seki K; Nishiuchi M; Shinji Y; Kiriyama K; Himeno S; Minami Y; Kashihara T; Kawakami F; Maeda H; Yabuuchi I; Nishioka M; Shirai Y; Fukuda K; Kiso S; Ito T; Igura T; Doi Y; Matsuzawa Y
Liver; 1997 Apr; 17(2):88-92. PubMed ID: 9138278
[TBL] [Abstract][Full Text] [Related]
37. Comparison of antiviral effect of lamivudine with interferon-alpha2a versus -alpha2b in children with chronic hepatitis B infection.
Ozgenc F; Dikici B; Targan S; Doganci T; Akman S; Aydogdu S; Yagci RV
Antivir Ther; 2004 Feb; 9(1):23-6. PubMed ID: 15040533
[TBL] [Abstract][Full Text] [Related]
38. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.
Antonelli G; Giannelli G; Currenti M; Simeoni E; Del Vecchio S; Maggi F; Pistello M; Roffi L; Pastore G; Chemello L; Dianzani F
Clin Exp Immunol; 1996 Jun; 104(3):384-7. PubMed ID: 9099919
[TBL] [Abstract][Full Text] [Related]
39. Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
Ascione A; De Luca M; Di Costanzo GG; Picciotto FP; Lanza AG; Canestrini C; Morisco F; Tuccillo C; Caporaso N
Curr Pharm Des; 2002; 8(11):977-80. PubMed ID: 11945144
[TBL] [Abstract][Full Text] [Related]
40. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
